What Intracort Treats: Main Uses and Benefits

Managing Severe Pain, Swelling, and Stiffness

This medication is commonly used to address symptom clusters that create noticeable functional strain, such as symptoms related to physical discomfort, stiffness, and significant tissue swelling often linked to inflammatory diseases. Intracort is applied across domains where additional symptomatic support is needed, particularly in conditions characterized by periods of heightened symptoms. It is considered relevant for easing the disruptive manifestations of severe asthma, Crohn's disease, and ulcerative colitis.

This medicine may be part of symptomatic management applied in contexts involving inflammatory or irritative processes. It offers symptomatic relief that helps patients cope more steadily with difficult episodes and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Supportive Relief for Symptoms Related to Irritation

“Intracort is applied in clinical settings that involve acute or unstable symptom patterns, supports patients during difficult episodes by easing distress when symptoms become more noticeable.”

Supporting Symptomatic Relief During Acute Episodes and Flares

Intracort is considered relevant in clinical settings that involve acute or unstable symptom patterns, such as acute episodes or autoimmune disease exacerbations. It is used for managing symptoms that may become more disruptive during flare-ups, generally contributes to improved day-to-day comfort, and may help with symptoms that interfere with daily functioning. Relevant in contexts involving heightened systemic burden, this medicine provides support that helps ease the overall symptom burden and supports patients during episodes of heightened discomfort.

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility and Contraindications

The ability to use Intracort (deflazacort) is strictly defined by regulatory documents, which establish population groups who are eligible, restricted, or absolutely prohibited from using the medicine.

Eligibility-Related Restrictions

Age-Related Rules: Safety and efficacy have not been established in children younger than two years of age. For older adults, no special precautions beyond those adopted for general glucocorticoid therapy are typically necessary.

Special Conditions: Use is restricted for patients who are to receive live or live-attenuated vaccines while taking immunosuppressive doses of the medicine. Due to the risk of exacerbation, special caution and monitoring are required for patients with pre-existing conditions such as diabetes mellitus or certain gastrointestinal disorders.

Physiological Status: Use during pregnancy or lactation is not recommended and should only be considered if the potential benefit definitively outweighs the possible risks.

Interactions with other medicines and products

Intracort (Deflazacort) is primarily metabolized through the Cytochrome P450 3A4 (CYP3A4) enzyme system. This metabolism is the basis for several clinically important drug interactions that modify the drug's exposure in the body.

Key Interaction Categories

Restrictions and Requirements

Regulatory documents advise specific constraints to manage interactions:

• Absorption Interference: Antacids containing aluminum or magnesium hydroxide must be administered with a separation of at least two hours from Intracort to ensure proper drug absorption.
• Dietary Restriction: Avoid consuming Grapefruit or Grapefruit Juice, as it can inhibit the CYP3A4 enzyme, leading to higher Intracort levels.
• Contraindicated Combination: Intracort should not be administered with live vaccines due to the drug's immunosuppressive effects.

The mechanism begins with the inactive compound, Deflazacort, which undergoes biotransformation by plasma esterases into its active metabolite, 21-desacetyl deflazacort (21-desDFZ). This metabolite acts as an agonist (activator) for the intracellular Glucocorticoid Receptor (GR), triggering the molecular events required to modulate gene transcription. The binding causes the GR to change conformation and translocate into the cell nucleus. Once activated, the GR complex enters the cell nucleus to modulate gene expression through two primary processes: transactivation (increasing transcription of anti-inflammatory genes like Lipocortin-1) and transrepression (decreasing transcription of pro-inflammatory genes driven by factors such as NF-κB). This dual control promotes a systemic shift in the expression profile of inflammatory signaling components. The consequence of this genomic activity is the indirect inhibition of the Eicosanoid Pathway (via Lipocortin-1 blocking Phospholipase A2), which limits the formation of mediators such as prostaglandins and leukotrienes. Furthermore, the mechanism results in reduced systemic immune cell function and decreased permeability of the vascular endothelium. These actions collectively establish a state of broad systemic immune and inflammatory modulation.

How to Use Intracort (Deflazacort) — Administration Guidelines

This section outlines the method for administering Intracort.

1. Dosing and Frequency

The standard prescribed dose is based on the patient's body weight, typically administered as 0.9 mg per kilogram of body weight per day. The total daily dose is taken once daily.

2. Dosage Forms and Route

Intracort is available in two oral forms: tablets (6 mg, 18 mg, 30 mg, and 36 mg) and an oral suspension (22.75 mg/mL). The route of administration for both forms is Oral (PO).

3. Administration Instructions

4. Special Use Procedures

• Age of Use: The medication is for use in patients 2 years of age and older.
• Dose Tapering: If treatment is to be stopped after more than a few days, the dosage is gradually decreased (tapered) under the supervision of a healthcare professional.
• Drug Interactions: If Intracort is taken with strong or moderate CYP3A4 inhibitors, the dose is reduced to one-third of the recommended daily dosage. Concomitant use with CYP3A4 inducers is generally avoided.

The clinical evaluation of Deflazacort has been reviewed through regulatory and peer-reviewed scientific sources. This section describes the types of studies that exist, the populations they examined, and the broad patterns observed in research.

Evidence for Use in Duchenne Muscular Dystrophy (DMD)

Research for this condition was based on Randomized Controlled Trials (RCTs) and long-term observational studies. These trials focused on pediatric males and monitored changes in motor function (measured by timed tests and muscle strength scales) and the time taken until the loss of independent ambulation (LoA). The body of evidence supporting this condition is categorized as High, reflecting multiple RCTs and extensive long-term observational data that document group patterns over time.

Evidence for Other Conditions

Deflazacort was studied for use in Idiopathic Nephrotic Syndrome (INS), primarily in pediatric patients through RCTs that evaluated remission rates and relapse frequency. The body of evidence supporting this use is categorized as Moderate. Furthermore, the compound was studied for use in General Systemic Inflammatory Conditions, such as chronic arthritis and systemic autoimmune diseases. Research in these contexts mostly consists of older Controlled Clinical Trials and equivalence studies monitoring disease activity scores and inflammation markers. The evidence for these general uses is categorized as Low.

Long-Term Data and Research Gaps

While the long-term observational data for DMD is substantial, follow-up durations were limited (e.g., six months to one year) for conditions like INS. This means that data related to the sustained patterns of response many years after starting treatment are still emerging. Research highlights that sample sizes were modest in some older trials, and comparative evidence is lacking for certain subgroups or when evaluating long-term outcomes for general inflammatory uses.

Key Studies & References Deflazacort versus Prednisolone in the Treatment of Newly Diagnosed Idiopathic Nephrotic Syndrome in Children (Comparative RCT)

Common questions about Intracort (FAQ)

Q: What is Intracort and how is it used?

Intracort is the brand name for a corticosteroid medication, specifically budesonide, which is used to treat inflammation. It is commonly administered as a nasal spray to manage symptoms associated with allergic rhinitis (hay fever), such as sneezing, runny nose, and nasal congestion. It may also be used in other formulations to treat inflammatory conditions like asthma or Crohn's disease, depending on the specific product and prescribed use.

Q: How long does it take for Intracort to start working?

Intracort generally does not provide immediate relief. For treating allergic rhinitis with the nasal spray, some people may start to notice an improvement in symptoms within 10 hours. However, the full benefit of the medication is typically seen after several days of regular use, often taking up to two weeks for maximum effect. Consistent and proper use, as directed by a healthcare provider, is crucial for achieving the best results.

Q: What are the common side effects of Intracort?

Like all medications, Intracort can cause side effects, though not everyone experiences them. When used as a nasal spray, common side effects may include:

• Nosebleed (epistaxis)
• Nasal irritation or dryness
• Sneezing
• Sore throat
• Cough

If Intracort is used in other forms, such as inhalation or oral capsules, the side effects can differ. It is important to discuss any side effects with a healthcare professional.

Q: Can Intracort be used during pregnancy or while breastfeeding?

• Pregnancy: The use of Intracort during pregnancy should be discussed with a healthcare provider. While studies have not shown a clear link to major birth defects, it is a Category B drug, meaning animal studies have not shown risk, but there are no adequate and well-controlled studies in pregnant women. It should only be used if the potential benefit justifies the potential risk to the fetus.
• Breastfeeding: Intracort is generally considered safe to use while breastfeeding, particularly when administered as a nasal spray. The amount of medication that passes into breast milk is usually very low. However, a healthcare professional should always be consulted to weigh the benefits against any potential risk to the infant.

Q: Does Intracort interact with other medications?

Yes, Intracort has the potential to interact with certain other medications, which may increase the level of Intracort in the body and raise the risk of side effects. Key interactions may include:

• CYP3A4 inhibitors: Medications that block the CYP3A4 enzyme, such as certain antifungal agents (e.g., ketoconazole) and HIV medications (e.g., ritonavir), can significantly increase the concentration of Intracort in the blood.
• Corticosteroids: Using Intracort concurrently with other corticosteroids may increase the risk of systemic corticosteroid side effects.

Patients should provide a complete list of all medications, supplements, and herbal products they are taking to their healthcare provider or pharmacist before starting Intracort.

How to Store and Dispose of Intracort?

Storage Conditions

Intracort (deflazacort) must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F and 77°F). It is required to keep the medicine in its original container and to protect it from moisture. When dispensing, the tablets must be in a well-closed, light-resistant container.

Stability and Child Safety

The oral suspension formulation must be discarded one month after the bottle has been first opened. The medication, in both forms, must be kept out of the reach of children.

Disposal Instructions

Unused or expired Intracort should not be kept. The official recommended method for disposal is utilizing a drug take-back program. If a program is not available, the product may be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash, following standard environmental guidelines.